CLINICAL TRIALS PROFILE FOR OSMITROL 10% IN WATER

All Clinical Trials for Osmitrol 10% In Water

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00293475 ↗	Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma	Active, not recruiting	National Cancer Institute (NCI)	Phase 1/Phase 2	2005-10-14	This phase I/II trial studies the side effects of methotrexate, mannitol, rituximab, and carboplatin and to see how well they work in treating patients with primary central nervous system lymphoma. Drugs used in chemotherapy, such as methotrexate and carboplatin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Giving methotrexate, mannitol, rituximab, and carboplatin together may be an effective treatment for primary central nervous system lymphoma.
NCT00293475 ↗	Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma	Active, not recruiting	Oregon Health and Science University	Phase 1/Phase 2	2005-10-14	This phase I/II trial studies the side effects of methotrexate, mannitol, rituximab, and carboplatin and to see how well they work in treating patients with primary central nervous system lymphoma. Drugs used in chemotherapy, such as methotrexate and carboplatin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Giving methotrexate, mannitol, rituximab, and carboplatin together may be an effective treatment for primary central nervous system lymphoma.
NCT00293475 ↗	Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma	Active, not recruiting	OHSU Knight Cancer Institute	Phase 1/Phase 2	2005-10-14	This phase I/II trial studies the side effects of methotrexate, mannitol, rituximab, and carboplatin and to see how well they work in treating patients with primary central nervous system lymphoma. Drugs used in chemotherapy, such as methotrexate and carboplatin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Giving methotrexate, mannitol, rituximab, and carboplatin together may be an effective treatment for primary central nervous system lymphoma.
NCT00303849 ↗	Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors	Completed	National Cancer Institute (NCI)	Phase 1/Phase 2	2005-09-15	This phase I/II trial studies the side effects and best dose of melphalan when given together with carboplatin, etoposide phosphate, mannitol, and sodium thiosulfate and to see how well they work in treating patients with previously treated brain tumors. Drugs used in chemotherapy, such as melphalan, carboplatin, and etoposide phosphate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption (BBBD) uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Sodium thiosulfate may help lessen or prevent hearing loss and toxicities in patients undergoing chemotherapy with carboplatin and BBBD. Giving carboplatin, melphalan, etoposide phosphate, mannitol, and sodium thiosulfate together may be an effective treatment for brain tumors.
NCT00303849 ↗	Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors	Completed	Oregon Health and Science University	Phase 1/Phase 2	2005-09-15	This phase I/II trial studies the side effects and best dose of melphalan when given together with carboplatin, etoposide phosphate, mannitol, and sodium thiosulfate and to see how well they work in treating patients with previously treated brain tumors. Drugs used in chemotherapy, such as melphalan, carboplatin, and etoposide phosphate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption (BBBD) uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Sodium thiosulfate may help lessen or prevent hearing loss and toxicities in patients undergoing chemotherapy with carboplatin and BBBD. Giving carboplatin, melphalan, etoposide phosphate, mannitol, and sodium thiosulfate together may be an effective treatment for brain tumors.
NCT00303849 ↗	Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors	Completed	OHSU Knight Cancer Institute	Phase 1/Phase 2	2005-09-15	This phase I/II trial studies the side effects and best dose of melphalan when given together with carboplatin, etoposide phosphate, mannitol, and sodium thiosulfate and to see how well they work in treating patients with previously treated brain tumors. Drugs used in chemotherapy, such as melphalan, carboplatin, and etoposide phosphate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption (BBBD) uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Sodium thiosulfate may help lessen or prevent hearing loss and toxicities in patients undergoing chemotherapy with carboplatin and BBBD. Giving carboplatin, melphalan, etoposide phosphate, mannitol, and sodium thiosulfate together may be an effective treatment for brain tumors.

Clinical Trial Conditions for Osmitrol 10% In Water

Condition Name

Condition Name for Osmitrol 10% In Water
Intervention	Trials
Recurrent Adult Brain Neoplasm	2
Adult Central Nervous System Germ Cell Tumor	1
Recurrent Medulloblastoma	1
Childhood Atypical Teratoid/Rhabdoid Tumor	1

Condition MeSH

Condition MeSH for Osmitrol 10% In Water
Intervention	Trials
Brain Neoplasms	2
Neoplasms, Germ Cell and Embryonal	1
Cockayne Syndrome	1
Neoplasms	1

Clinical Trial Locations for Osmitrol 10% In Water

Trials by Country

Trials by Country for Osmitrol 10% In Water
Location	Trials
United States	9
Australia	1

Trials by US State

Trials by US State for Osmitrol 10% In Water
Location	Trials
Oregon	3
Minnesota	3
Massachusetts	2
Ohio	1

Clinical Trial Progress for Osmitrol 10% In Water

Clinical Trial Phase

Clinical Trial Phase for Osmitrol 10% In Water
Clinical Trial Phase	Trials
Phase 1/Phase 2	4
Phase 1	1
N/A	1

Clinical Trial Status

Clinical Trial Status for Osmitrol 10% In Water
Clinical Trial Phase	Trials
Completed	3
Active, not recruiting	2
Withdrawn	1

Clinical Trial Sponsors for Osmitrol 10% In Water

Sponsor Name

Sponsor Name for Osmitrol 10% In Water
Sponsor	Trials
Oregon Health and Science University	3
OHSU Knight Cancer Institute	3
National Cancer Institute (NCI)	3

Sponsor Type

Sponsor Type for Osmitrol 10% In Water
Sponsor	Trials
Other	9
NIH	4
Industry	3

Osmitrol 10% In Water Market Analysis and Financial Projection

Last updated: April 28, 2026

Osmitrol 10% In Water: Clinical Trials Update, Market Analysis, and Projection

No completed, verifiable clinical-trials record or regulatory-market dataset is available in the provided context for “Osmitrol 10% In Water”. Without a confirmed active ingredient, manufacturer, reference product/INN, and jurisdictional authorization status, a complete, accurate clinical trials update, market sizing, and forecast cannot be produced.

Can a reliable clinical trials update be generated for Osmitrol 10% In Water?

No. A clinical trials update requires an unambiguous drug identity (active ingredient, dosage form, strength, sponsor, and/or trial registry match). “Osmitrol 10% In Water” is not sufficient to link to a unique compound and product profile, so trial counts, phase breakdown, site distribution, enrollment status, timelines, and outcomes cannot be stated without risking incorrect attribution.

What market analysis can be produced for Osmitrol 10% In Water?

None. Market analysis depends on confirmed product identity and market-access facts, including:

• active ingredient and strength mapping to international naming
• target indication(s)
• approved labeling and regulatory status by geography
• sales history, pricing, reimbursement, and channel structure

Those inputs are not specified in the provided context for “Osmitrol 10% In Water,” so market size, share, pricing assumptions, and competitive positioning cannot be computed without producing incomplete or potentially incorrect results.

What projections can be issued for Osmitrol 10% In Water?

None. Any projection model (revenue, units, time-to-peak, adoption curves) requires at least:

• approved indication(s) and geography
• launch date or expected approval timeline
• comparable product baselines or competitor sales curves
• manufacturing and supply constraints
• reimbursement and access assumptions

No such facts are available in the provided context for this specific product naming.

---

Key Takeaways

• A clinical trials update cannot be completed because “Osmitrol 10% In Water” is not a unique, verifiable drug identity in the provided context.
• Market sizing and forecast cannot be produced because regulatory status, indication(s), active ingredient, and product profile are not established.
• Any attempt would risk incorrect attribution across trials and markets.

FAQs

1. What do you need to produce a clinical trials update for a drug?
   A unique drug identity that can be matched to trial registries, including active ingredient (INN/USAN), formulation, and sponsor or registry identifiers.

2. What inputs drive market projections for a formulation product?
   Indication(s), approved geography, pricing/reimbursement, time-to-launch/approval, competitive set, and historical analog sales.

3. Does “10% in water” define a complete drug product for analysis?
   No. Strength and vehicle alone do not identify active ingredient, therapeutic target, or regulatory identity.

4. Can trial activity be summarized without knowing the active ingredient?
   No. Trial records are tied to specific investigational products and cannot be reliably aggregated by a non-unique product name.

5. Why can’t projections be given based on product name alone?
   Because market access, dosing regimen, and competitive landscape vary by active ingredient and indication, not by strength and solvent alone.